Book on hepatitis from page 376 to 385

Book on hepatitis from page 376 to 385

376  Hepatology 2012
Berenguer M (b), Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential
risks associated with antiviral therapy in liver transplant recipients with recurrent
hepatitis C. Liver Transpl 2006;12:1067-76.
Berenguer M. Recurrent hepatitis C: worse outcomes established, interventions still
inadequate. Liver Transplantation 2007;13:641-3.
Berenguer M, Palau A, Aquilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral
therapy in patients with recurrent hepatitis C following liver transplantation. Am J
Transplant 2008;8:679-87.
Berenguer M. Hot topic in hepatitis C virus research: The type of immunosuppression does not
matter. Liver Transplant 2011;17:S24-S28.
Bizollon T, Ahmed SN, Radenne S, et al. Long term histological improvement and clearance of
intrahepatic hepatitis C virus RNA following sustained viral response to interferon-ribavirin combination therapy in liver transplant patients with hepatitis C virus
recurrence. Gut 2005;52:283-7.
Brandhagen DJ. Liver transplantation for hereditary hemochromatosis. Liver Transpl
2001;7:663-7.
Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against
hepatitis C recurrence after liver transplantation. Liver Transpl 2002;8:884-8.
Broelsch CE, Whitington PF, Emond JC, et al. Liver transplantation in children from living
related donors. Surgical techniques and results. Ann Surg 1991;214:428-37.
Buell JF, Gross TG, Woodle ES. Malignancy after transplantation.Transplantation
2005;15:S254-64.
Buis CI, Geuken E, Visser DS, Kuipers F, Haagsma EB, Verkade HJ, et al. Altered bile
composition after liver transplantation is associated with the development of
nonanastomotic biliary strictures. J Hepatol 2009;50:69-79.
Bundesärztekammer. Richtlinien zur Organtransplantation gem. §16 TPG. Deutsches Ärzteblatt
2008;105:A1461-4.
Burra P, Lucey MR. Liver transplantation in alcoholic patients. Transpl Int 2005;18:491-8.
Burra P, Senzolo M, Adam R, et al. Liver transplantation for alcoholic liver disease in Europe: a
study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010
Jan;10:138-48.
Buti M, Mas A, Prieto M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B
immune globulin plays an important role in the long-term prevention of hepatitis B
virus recurrence. Transplantation 2007;84:650-4.
Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: A randomized controlled trial of
peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver
transplantation for hepatitis C virus. Liver Transpl 2011;17:528-38.
Cai CJ, Lu MQ, Chen YH, Zhao H, Li MR, Chen GH. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant 2011; doi:
10.1111/j.1399-0012.2011.01448.x.
Cannon JA. Organs. Transplant Bull 1956;3-7.
Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric
anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002;8:123-31.
Campsen J , Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis
and the success of aggressive corticosteroid withdrawal. Liver Transpl 2008;14:1281-6.
Cantarovich M, Tzimas GN, Barkun J, Deschênes M, Alpert E, Tchervenkov J. Efficacy of
mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in
long-term liver-transplant patients with renal dysfunction. Transplantation 2003;76:98-102.
Carbone M, Neuberger J. Liver transplantation in PBC and PSC: indications and disease
recurrence. Clin Res Hepatol Gastroenterol 2011;35:446-54.
Castells L, Vargas V, Aleende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver
transplantation. J Hepatol 2005;43:53-9.
Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver
transplantation: two randomized, controlled trials. Hepatology 2005;41:289-98.
Chan G, Taqi A, Marotta P, et al. Long-term outcomes of emergency liver transplantation for
acute liver failure. Liver Transpl. 2009 Dec;15:1696-702.
Update in Transplant Hepatology  377
Charatcharoenwitthaya P, Pimentel S, Talwalkar, et al. Long-term survival and impact of
ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver
transplantation. Liver Transpl 2007;13:1236-45.
Choi PC, Kim HJ, Choi WH, et al. Model for end-stage liver disease, model for end-stage liver
disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of
complications of liver cirrhosis. Liver Int 2009;29:221-6.
Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary
sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:138-43.
Cicinnati VR (a), Yu Z, Klein CG, et al. Clinical trial: switch to combined mycophenolate mofetil
and minimal dose calcineurin inhibitor in stable liver transplant patients-assessment
of renal and allograft function, cardiovascular risk factors and immune monitoring.
Aliment Pharmacol Ther 2007;26:1195-208.
Cicinnati V (b), Iacob S, Klein C, et al. Ribavirin with either standard or pegylated interferon to
treat recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther
2007;26:291-303.
Cornberg M, Protzer U, Petersen J, et al. Prophylaxis, diagnosis and therapy of hepatitis B
virus infection - the German guideline. Z Gastroenterol. 2011;49:871-930.
Craig DG, Ford AC, Hayes PC, Simpson KJ. Systematic review: prognostic tests of
paracetamol-induced acute liver failure. Aliment Pharmacol Ther 2010;31:1064-76.
Créput C, Blandin F, Deroure B, et al. Long-term effects of calcineurin inhibitor conversion to
mycophenolate mofetil on renal function after liver transplantation. Liver Transpl
2007;13:1004-10.
Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability
and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver
transplantation. Liver Transpl 2002;8:350-5.
J S Cross T, Jothimani D, Heneghan MA, Harrison PM. Non-invasive assessment of fibrosis in
liver grafts due to hepatitis C virus recurrence. Clin Transplant 2011;25:345-51.
Daly I, Jain A, Reyes J, Fung J. Mycophenolate mofetil for treatment of chronic rejection in liver
allograft under tacrolimus. Transplant Proc 2002;34:1503.
Dar FS, Faraj W, Zaman MB, Bartlett A, et al. Outcome of liver transplantation in hereditary
hemochromatosis. Transpl Int 2009;22:717-24.
Demetris AJ, Murase N, Lee RG, et al. Chronic rejection. A general overview of histopathology
and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann
Transplant 1997;2:27-44.
Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after
transplantation of the liver or other solid organs. Liver Transpl 2008;14:159-72.
Di Benedetto F, Tarantino G, Montalti R, et al. Sorafenib before liver transplantation for
hepatocellular carcinoma: risk or give up. Transpl Int 2011; 24:e97; doi:
10.1111/j.1432-2277.2011.01329.x.
DiMartini A, Dew MA, Fitzgerald MG, Fontes P. Clusters of alcohol use disorders diagnostic
criteria and predictors of alcohol use after liver transplantation for alcoholic liver
disease. Psychosomatics 2008;49:332-40.
Duclos-Vallée JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted
for autoimmune hepatitis: histological recurrence precedes clinical and biochemical
recurrence. Gut. 2003 Jun;52:893-7.
Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular
carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.
Ann Surg 2007;246:502-9.
Dutkowski P, Oberkofler CE, Béchir M, et al. The model for end-stage liver disease allocation
system for liver transplantation saves lives, but increases morbidity and cost: a
prospective outcome analysis. Liver Transpl 2011;17:674-84.
Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection
after solid organ transplantation. Drugs 2010; 70:965-81.
Erim Y, Böttcher M, Dahmen U, Beck O, Broelsch CE, Helander A. Urinary ethyl glucuronide
testing detects alcohol consumption in alcoholic liver disease patients awaiting liver
transplantation. Liver Transpl 2007;13:757-61.
Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low
accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-62.
Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft
failure: the concept of a donor risk index. Am J Transplant 2006;6:783-90.
378  Hepatology 2012
Fevery J, Henckaerts L, Van Oirbeek R, et al. Malignancies and mortality in 200 patients with
primary sclerosering cholangitis: a long-term single-centre study. Liver Int 2012
32:214-22.
Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological
recurrence rate in HCV+ liver transplant recipients given basiliximab + steroids or
basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation
2004;78:1488-95.
Finkelstein SD, Marsh W, Demetris AJ, et al. Microdissection-based allelo-typing discriminates
de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology
2003;37:871-9.
Finkenstedt A, Graziadei IW, Oberaigner W, et al. Extensive surveillance promotes early
diagnosis and improved survival of de novo malignancies in liver transplant
recipients. Am J Transplant 2009; 9:2355-61.
Forman LM, Lewis DJ, Berlin JA, et al. The association between hepatitis C infection and
survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-96.
Frilling A, Malago M, Weber F, et al. Liver transplantation for patients with metastatic endocrine
tumors. Liver Transpl 2006;12:1089-96.
Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular
carcinoma before liver transplantation: necessity or option? Liver Int 2011;31:1081-9.
Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver
transplantation: a major cause of late death. Liver Transpl 2001;7:S109-18.
Fung J, Cheung C, Chan SC, Yuen MF. Entecavir monotherapy is effective in suppressing
hepatitis B virus after liver transplantation. Gastroenterology 2011;141:1212-9.
Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa
monotherapy for hepatitis C recurrence after liver transplantation. Hepatology
1998;27:1403-7.
Gane E, Strasser SI, Patterson S, et al. A prospective study on the safety and efficacy of
lamivudine and adefovir dipivoxil prophylaxis in HBsAg positive liver transplantation
candidates. Hepatology 2007;46:479A.
Garcia CE, Ribeiro HB, Garcia RL, et al. Mycophenolate mofetil in stable liver transplant
patients with calcineurin inhibitor-induced renal impairment: single-center experience.
Transplant Proc 2003;35:1131-2.
Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the
pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-7.
Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver
metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch
Surg 2011;146:953-8.
Germani G, Pleguezuelo M, Villamil F, et al. Azathioprine in liver transplantation: a reevaluation
of its use and a comparison with mycophenolate mofetil. Am J Transplant
2009;9:1725-31.
Ghalib R, Pandula R, Kadhim T, et al. Treatment of recurrent hepatitis C after liver
transplantation with alpha-2b interferon plus ribavirin. Hepatology 2000;32:291A.
Gonwa TA, Mai ML, Melton LB, Hays SR, et al. End-stage renal disease (ESRD) after
orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk
of development and treatment. Transplantation 2001;72:1934-9.
Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after
orthotopic liver transplantation. Liver Transpl 2001;7:302-10.
Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver
Transpl 2009;15:126-35.
Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary
sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997;225:472-81.
Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver
transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-7.
Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver
Transpl 2002;8:575-81.
Graziadei IW, Schwaighofer H, Koch R, et al. Long-term outcome of endoscopic treatment of
biliary strictures after liver transplantation. Liver Transpl 2006;12:718-25.
Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic
tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.
Nat Med 2002;8:128-35.
Update in Transplant Hepatology  379
Haber PS, McCaughan GW. "I'll never touch it again, doctor!"-harmful drinking after liver
transplantation. Hepatology 2007;46:1302-4.
Hanouneh IA, Macaron C, Lopez R. Risk of colonic neoplasia after liver transplantation for
primary sclerosing cholangitis. Inflamm Bowel Dis 2012;18:269-74.
Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P. Switching to sirolimus-based immune
suppression after liver transplantation is safe and effective: a single-center
experience. Transplantation 2011;91:128-32.
Hashemi N, Araya V, Tufail K, et al. An extended treatment protocol with pegylated interferon
and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol
2011;3:198-204.
Hashimoto E, Shimada M, Noguchi S, et al. Disease recurrence after living liver transplantation
for primary biliary cirrhosis: a clinical and histological follow-up study. Liver Transpl
2001;7:588-95.
Heimbach JK. Successful liver transplantation for hilar cholangiocarcinoma. Curr Opin
Gastroenterol. 2008;24:384-8.
Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma
with living-donor liver transplantation?-no, never. J Hepatol 2005;43:573-7.
Ho GT, Seddon AJ, Therapondos G, Satsangi J,Hayes PC. The clinical course of ulcerative
colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further
appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol
2005;17:1379-85.
Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation
for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single
center. Arch Surg 2011;146:683-9.
Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney
transplant recipients is associated with long-term reduction in cytomegalovirus
disease: two-year results of the IMPACT study Transplantation 2010; 27;90:1427-31.
Hytiroglou P, Gutierrez JA, Freni M, et al. Recurrence of primary biliary cirrhosis and
development of autoimmune hepatitis after liver transplant: A blind histologic study.
Hepatol Res 2009;39:577-84.
Iacob S, Cicinnati V, Hilgard P, et al. Predictors of graft and patient survival in hepatitis C virus
(HCV) recipients: model to predict HCV cirrhosis after liver transplantation.
Transplantation 2007;84:56-63.
Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with
hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol
2007;46:185-8.
Jacob DA, Neumann UP, Bahra M, et al. Long-term follow-up after recurrence of primary biliary
cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006;20:211-20.
Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective
randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis
C. Liver Tranpl 2002;8:47-9.
Jelic S, Sotiropoulos GC; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2010;21:59-64.
Jiao ZY, Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver
transplantation using lamivudine combined with hepatitis B immune globulin
according to the titer of antibody to hepatitis B surface antigen. Transplant Proc
2007;39:1533-6.
Jimenez C, Marques E, Manrique A, al. Incidence and risk factors of development of lung
tumors after liver transplantation. Transplant Proc 2005;37:3970-2.
John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver
transplantation compared with those without diabetes mellitus. Liver Transpl
2002;8:708-13.
Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver
transplantation. Curr Opin Organ Transplant 2011;16:274-80.
Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000;33:308-12.
Karlas T, Hartmann J, Weimann A, et al. Prevention of lamivudine-resistant hepatitis B
recurrence after liver transplantation with entecavir plus tenofovir combination
therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis
2011;13:299-302.
380  Hepatology 2012
Kasturi KS, Chennareddygari S, Mummadi RR. Effect of bisphosphonates on bone mineral
density in liver transplant patients: a meta-analysis and systematic review of
randomized controlled trials. Transpl Int 2010;23(2):200-7.
Kawahara T, Asthana S, Kneteman NM. m-TOR inhibitors: What role in liver transplantation? J
Hepatol 2011; Jul 23. [Epub ahead of print].
Kawasaki S, Makuuchi M, Matsunami H, et al. Living related liver transplantation in adults. Ann
Surg 1998;227:269-74.
Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrypsin deficiency: outcomes after liver
transplantation. Transplant Proc 2008;40:1492-4.
Khalaf H, Alsuhaibani H, Al-Sugair A et al. Use of yttrium-90 microsphere radioembolization of
hepatocellular carcinoma as downstaging and bridge before liver transplantation: a
case report. Transplant Proc 2010;42:994-8.
Kizilisik TA, Sebayel M, Hammad A, al-Traif I, Ramirez CG, Abdulla A. Hepatitis C recurrence
in liver transplant recipients. Transplant Proc 1997;29:2875-7.
Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with
daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3
study. Liver Transpl 2007;13:1521-31.
Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver
transplantation in the presence of extended criteria for hepatocellular carcinoma.
Liver Transpl 2004;10:1301-11.
Knight SR, Friend PJ, Morris PJ. Role of transplantation in the management of hepatic
malignancy. Br J Surg 2007;94:1319-30.
Konrad T, Steinmüller T, Vicini P, et al. Regulation of glucose tolerance in patients after liver
transplantation: impact of cyclosporin versus tacrolimus therapy. Transplantation
2000;69: 2072-8.
Lai JC, Verna EC, Brown RS Jr, et al. Hepatitis C virus-infected women have a higher risk of
advanced fibrosis and graft loss after liver transplantation than men. Hepatology
2011;54:418-24.
Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl
2003;9:S63-6.
Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103
patients. Transplantation 1998;66:1307-12.
Leithead JA, Ferguson JW, Bates CM, Davidson JS, Simpson KJ, Hayes PC. Chronic kidney
disease after liver transplantation for acute liver failure is not associated with
perioperative renal dysfunction. Am J Transplant 2011;11:1905-15.
Lerut J, Bonaccorsi-Riani E, Finet P, Gianello P. Minimization of steroids in liver transplantation.
Transpl Int 2009; 22:2-19.
Levitsky J, Thudi K, Ison MG, Wang E, Abecassis M. Alemtuzumab induction in non-hepatitis C
positive liver transplant recipients. Liver Transpl 2011;17:32-7.
Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for
hepatocellular carcinoma: A meta-analysis. Liver Transpl 2011. doi: 10.1002/lt.22441.
[Epub ahead of print]
Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for
primary biliary cirrhosis: retrospective analysis of 400 patients in a single center.
Hepatology 2001;33:22-7.
Liu X, Ling Z, Li L, Ruan B. Invasive fungal infections in liver transplantation. Int J Infect Dis
2011;15:e298-304.
Llado L, Fabregat J, Castellote J, et al. Impact of immunosuppression without steroids on
rejection and hepatitis C virus evolution after liver transplantation: results of a
prospective randomized study. Liver Transpl 2008;14:1752-60.
Lo CM, Fan ST, Liu CL, et al. Lessons learned from one hundred right lobe living donor liver
transplants. Ann Surg 2004;240:151-8.
Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B
with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus
lamivudine. Liver Transpl 2005;11:807-13.
Lo CM. Liver transplantation for acute liver failure: not too early but never too late. Liver Transpl
2008 Sep;14:1243-4.
Marsh JW, Finkelstein SD, Demetris AJ, et al. Genotyping of hepatocellular carcinoma in liver
transplant recipients adds predictive power for determining recurrence-free survival.
Liver Transpl 2003:9:664-71.
Update in Transplant Hepatology  381
Martin AP, Bartels M, Redlich J, Hauss J, Fangmann J. A single center experience with liver
transplantation for Wilson's disease. Clin Transplant 2008;22:216-21.
Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis
C virus-infected liver transplant recipients on recurrent hepatitis: a prospective,
randomized trial. Liver Transpl 2004;10:1258-62.
Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence
after liver transplantation in cirrhotic patients treated with lamivudine and passive
immunoprophylaxis. J Hepatol 2001;34:903-10.
Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after
liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005;
11:532-8.
Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and
everolimus monotherapy in de novo liver transplant recipients preserves renal
function. Am J Transplant 2010;10:2252-62.
Massie AB, Caffo B, Gentry SE, Hall EC. MELD Exceptions and Rates of Waiting List
Outcomes. Am J Transplant 2011;11:2362-71.
Masuoka HC, Rosen CB. Transplantation for cholangiocarcinoma. Clin Liver Dis 2011;15:699-715.
McCaughan GW, Zekry A. Impact of immunosuppression on immunopathogenesis of liver
damage in hepatitis C virus-infected recipients following liver transplantation. Liver
Transpl 2003;9:S21-7.
McKenna GJ, Trotter JF, Klintmalm E, Limiting hepatitis C virus progression in liver transplant
recipients using sirolimus-based immunosuppression. Am J Transplant
2011;11:2379-87.
Melero J, Berenguer M. Antiviral therapy in patients with HCV-cirrhosis. Ann Hepatol
2009;8:292-7.
Mendes F, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver
Dis. 2011;15:859-78.
Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J
Transplant 2005;5:307-13.
Merli M, Giannelli V, Gentili F, et al. Ribavirin priming improves the virological response to
antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
Antivir Ther 2011;16:879-85.
Moini M, Mistry P, Schilsky ML. Liver transplantation for inherited metabolic disorders of the
liver. Curr Opin Organ Transplant 2010;15:269-76.
Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune
hepatitis in liver transplant recipients. Liver Transpl 2002;8:519-26.
Montano-Loza AJ, Wasilenko S, Bintner J, Mason AL. Cyclosporine A protects against primary
biliary cirrhosis recurrence after liver transplantation. Am J Transplant 2010;10:852-8.
Moon DB, Lee SG. Liver transplantation. Liver Transpl 2011;doi:10.1002/lt.22455 [Epub ahead
of print].
Moreira Kulak CA, Cochenski B, Borba VZ, Kulak J, et al. Post-transplantation osteoporosis.
Arq Bras Endocrinol Metab 2010;54:143-9.
Moreno JM, Rubio E, Pons F, et al. Usefulness of mycophenolate mofetil in patients with
chronic renal insufficiency after liver transplantation. Transplant Proc 2003;35:715-7.
Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E, et al. Mycophenolate mofetil
can be used as monotherapy late after liver transplantation. Am J Transplant
2004;4:1650-5.
Morioka D (a), Egawa H, Kasahara M, et al. Impact of human leukocyte antigen mismatching
on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver
Transpl 2007;13:80-90.
Morioka D (b), Egawa H, Kasahara M, et al. Outcomes of adult-to-adult living donor liver
transplantation. A single institution`s experience with 335 consecutive cases. Ann
Surg 2007;245:315-25.
Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B
immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver
transplantation. J Hepatol 2001;34:888-94.
Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver
transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant
2006;20:206-10.
382  Hepatology 2012
Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with
hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007;52:2497-500.
Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl
Surg 1999;5:S30-6.
Nikolaidis N, Vassiliadis T, Giouleme O, et al. Effect of lamivudine treatment in patients with
decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis
B. Clin Transplant 2005;19:321-6.
Pabón V, Dumortier J, Gincul R, et al. Long-term results of liver transplantation for Wilson's
disease. Gastroenterol Clin Biol 2008;32:378-81.
Pascher A, Sauer IM, Walter M, et al. Donor evaluation, donor risks, donor outcome, and donor
quality of life in adult-to-adult living donor liver transplantation. Liver Transpl
2002;8:829-37.
Pascher A, Neuhaus P. Bile duct complications after liver transplantation. Transpl Int
2005;18:627-42.
Patel S, Orlaoff M, Tsoulfas G, et al. Living donor liver transplantation in the United States:
identifying donors at risk for perioperative complications. Am J Transplant
2007;7:2344-9.
Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir
for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J
Transplant 2004;4:611-20.
Perkins JD. Biliary tract complications: The most common postoperative complication in living
liver donors. Liver Transpl 2008:14:1372-7.
Perney P, Bismuth M, Sigaud H, et al. Are preoperative patterns of alcohol consumption
predictive of relapse after liver transplantation for alcoholic liver disease? Transpl Int
2005;18:1292-7.
Pfitzmann R, Schwenzer J, Rayes N, Seehofer D, Neuhaus R, Nüssler NC. Long-term survival
and predictors of relapse after orthotopic liver transplantation for alcoholic liver
disease. Liver Transpl 2007;13:197-205.
Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy
reduces mortality in HCV reinfection after liver transplantation. J Hepatol
2007:46:459-65.
Pomfret EA, Washburn K, Wald C et al. Report of a national conference on liver allocation in
patients with hepatocellular carcinoma in the United States. Liver Transpl.
2010;16:262-78.
Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver
transplantation. Transplantation 1998;66:1645-50.
Qin YS, Li ZS, Sun ZX, Wu RP, Wang N, Yao YZ. Endoscopic management of biliary
complications after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int
2006;5:39-42.
Qiu J, Ozawa M, Terasaki PI. Liver transplantation in the United States. Clin Transpl 2005:17-28.
Radunz S, Juntermanns B, Kaiser GM et al. Efficacy and safety of linezolid in liver transplant
patients. Transpl Infect Dis 2011;13:353-8.
Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil
monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction
after liver transplantation. Transplantation 2003;75:186-90.
Razonable RR, Zerr DM and the AST Infectious Diseases Community of Practice. HHV-6,
HHV-7 and HHV-8 in Solid Organ Transplant Recipients. Am J Transplant 2009; 9
S97-S103.
Rea DJ, Heimbach JK, Rosen CB. Liver transplantation with neoadjuvant chemoradiation is
more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451-8.
ReViS-TC Study Group. Cyclosporine a-based immunosuppression reduces relapse rate after
antiviral therapy in transplanted patients with hepatitis C virus infection: a large
multicenter cohort study. Transplantation 2011;92:334-40.
Ringe B, Wittekind C, Bechstein WO, et al. The role of liver transplantation in hepatobiliary
malignancy. A retrospective analysis of 95 patients with particular regard to tumor
stage and recurrence. Ann Surg 1989;209:88-98.
Roayie K, Feng S. Allocation policy for hepatocellular carcinoma in the MELD era: room for
improvement? Liver Transpl 2007;13:S36-43.
Update in Transplant Hepatology  383
Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe
recurrence of hepatitis C after liver transplantation. Am J Gastroenterol
1997;92:1453-7.
Rubín A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol
Gastroenterol 2011 [Epub ahead of print].
Rudraraju M, Osowo AT, Singh V, Carey EJ. Do patients need more frequent colonoscopic
surveillance after liver transplantation? Transplant Proc 2008;40:1522-4.
Saab S, Niho H, Comulada S, et al. Mortality predictors in liver transplant recipients with
recurrent hepatitis C cirrhosis. Liver Int 2005;25:940-5.
Saab S, Desai S, Tsaoi D, et al. Posttransplantation hepatitis B prophylaxis with combination
oral nucleoside and nucleotide analog therapy. Am J Transplant 2011;11:511-7.
Saliba F, Dharancy S, Lorho R, et al. Conversion to everolimus in maintenance liver transplant
patients: a multicenter, retrospective analysis. Liver Transpl 2011;17:905-13.
Samonakis DN, Cholongitas E, Triantos CK, et al. Sustained, spontaneous disappearance of
serum-HCV under immunosuppression after liver transplantation for hepatitis C
cirrhosis. J Hepatol 2005;43:1091-3.
Sanchez EQ, Martin AP, Ikegami T, et al. Sirolimus conversion after liver transplantation:
improvement in measured glomerular filtration rate after 2 years. Transplant Proc
2005;37:4416-23.
Saner FH, Cicinnati VR, Sotiropoulos G, Beckebaum S. Strategies to prevent or reduce acute
and chronic kidney injury in liver transplantation. Liver Int 2011;. [Epub ahead of
print].
Schacherer D, Zeitoun M, Buttner R, et al. Sirolimus-induced drug fever and ciclosporin-induced leukencephalopathia with seizures in one liver transplant recipient. World J
Gastroenterol 2007;13:6090-3.
Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver
transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
Liver Transpl 2007;13:349-60.
Schlitt HJ, Loss M, Scherer M, et al. Current developments in liver transplantation in Germany:
MELD-based organ allocation and incentives for transplant centres. Z Gastroenterol
2011;49: 30-8. PMID 21225535.
Schmeding M, Kiessling A, Neuhaus R et al. Mycophenolate mofetil monotherapy in liver
transplantation: 5-year follow-up of a prospective randomized trial. Transplantation
2011;92:923-9.
Schnitzbauer AA (a), Scherer MN, Rochon J, et al. Study protocol: a pilot study to determine
the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study.
BMC Nephrol 2010;11:24.
Schnitzbauer AA (b), Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial
comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in
patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer
2010;10:190.
Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability, and efficacy of preemptive
antiviral therapy in hepatitis C infected patients undergoing liver transplantation. Am J
Transplant 2005;5:118-24.
Silva MF, Sherman M. Criteria for liver transplantation for HCC: What should the limits be? J
Hepatol 2011;55:1137-47.
Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver
transplantation. Am J Transplant 2010;10:720-6.
Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver
transplant: role of immunity, diagnosis, and management. Pediatr Transplant
2002;6:280-7.
Soliman T, Hetz H, Burghuber C. Short-term induction therapy with anti-thymocyte globulin and
delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl
2007;13:1039-44.
Sotiropoulos GC, Molmanti EP, Lösch C, Beckebaum S, Brolesch CE, Lang H. Meta-analysis of
tumor recurrence after liver transplantation for hepatocellular carcinoma based on
1,198 cases. Eur J Med Res 2007;12:527-34.
Sotiropoulos CG (a), Beckebaum S, Lang H, et al. Single-center experience on liver
transplantation for hepatocellular carcinoma arising in alcoholic cirrhosis: results and
ethical issues. Eur Surg Res 2008;40:7-13.
384  Hepatology 2012
Sotiropoulos GC (b), Lang H, Sgourakis G, et al. Liberal policy in living donor liver
transplantation for hepatocellular carcinoma: Lessons learned. Dig Dis Sci 2008.
[Epub ahead of print].
Starzl TE, Marchioro TL, Von Kaulla KN, et al. Homotransplantation of the liver in humans. Surg
Gynecol Obstet 1963;117:659-76.
Starzl TE, Groth CG, Brettschneider L, et al. Orthotopic homotransplantation of the human liver.
Ann Surg 1968;168:392-415.
Staufer K, Andresen H, Vettorazzi E, et al. Urinary ethyl glucuronide as a novel screening tool
in patients pre and post liver transplantation improves detection of alcohol
consumption. Hepatology 2011; doi: 10.1002/hep.24596. [Epub ahead of print]
Sugawara Y, Makuuchi M. Technical advances in living-related liver transplantation. J
Hepatobiliary Pancreat Surg 1999;6:245-53.
Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004;78:1308-11.
Sugawara Y, Makuuchi M. Living donor liver transplantation: present status and recent
advances. Br Med Bull 2005;75-76:15-28.
Sutcliffe RP, Maguire DD, Muiesan P, et al. Liver transplantation for Wilson's disease: long-term
results and quality-of-life assessment. Transplantation 2003;75:1003-6.
Sylvestre PB, Batts KP, Burgart LJ, Poterucha JJ, Wiesner RH. Recurrence of primary biliary
cirrhosis after liver transplantation: Histologic estimate of incidence and natural
history. Liver Transpl 2003;9:1086-93.
Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: recurrence and
disease progression in 300 patients. Liver Transpl 2000;6:553-61.
Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, van Thiel DH. Infection with
chronic hepatitis C virus and liver transplantation: a role for interferon therapy before
transplantation. Liver Transpl 2003;9:905-15.
Togashi J, Sugawara Y, Tamura S, et al. Basiliximab as therapy for acute rejection after liver
transplantation for hepatitis C virus cirrhosis. Biosci Trends 2011;5:57-60.
Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferon-alpha in antiviral
regimens for post-transplant recurrent hepatitis C: comparison of tolerability and
efficacy. J Gastroenterol Hepatol 2005;20:577-82.
Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver
transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
Transplantation 2007;83:1162-8.
Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular
carcinoma. J Hepatol 2010;52:930-6.
Tournoux-Facon C, Paoletti X, Barbare JC, et al. Development and validation of a new
prognostic score of death for patients with hepatocellular carcinoma in palliative
setting. J Hepatol 2011;54:108-14.
Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver
transplantation and hepatitis C virus: systematic review of antiviral therapy.
Transplantation 2005;79:261-8.
Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results,
and management of recurrent disease. Semin Liver Dis 2009;29:286-96.
Tung BY, Kimmey MB. Biliary complications of orthotopic liver transplantation. Dig Dis
1999;17:133-44.
Ulrich C, Degen A, Patel MJ, Stockfleth. Sunscreens in organ transplant patients. Nephrol Dial
Transplant 2008;23:1805-8.
Vagefi PA, Ascher NL, Freise CE, Dodge JL, Roberts JP. The use of living donor liver
transplantation varies with the availability of deceased donor liver transplantation.
Liver Transpl 2011; doi: 10.1002/lt.22455.
Valentin-Gamazo C, Malago M, Karliova M, et al. Experience after the evaluation of 700
potential donors for living donor liver transplantation in a single center. Liver Transpl
2004; 10: 1087-96.
Vallejo GH, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver
transplantation.Crit Rev Oncol Hematol 2005;56:87-99.
Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing
cholangitis of liver allograft. Lancet 2002;360:1943-4.
Verdonk RC, Buis CI, van der Jagt EJ, et al. Nonanastomotic biliary strictures after liver
transplantation, part 2: Management, outcome, and risk factors for disease
progression. Liver Transpl 2007;13:725-32.
Update in Transplant Hepatology  385
Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune
hepatitis. Clin Transplant 2004;18:62-9.
Washington K. Update on post-liver transplantation infections, malignancies, and surgical
complications. Adv Anat Pathol 2005;12:221-6.
Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for
liver transplantation. Transplantation 1999;67:505-9.
Weber NK, Forman LM, Trotter JF. HBIg discontinuation with maintenance oral anti-viral herapy
and HBV vaccination in liver transplant recipients. Dig Dis Sci 2010; 55: 505-9.
Weiss KH, Gotthardt D, Schmidt J, et al. Liver transplantation for metabolic liver diseases in
adults: indications and outcome. Nephrol Dial Transplant 2007;22(Suppl 8):viii9-12.
Weismüller TJ, Prokein J, Becker T, et al. Prediction of survival after liver transplantation by
pre-transplant parameters. Scand J Gastroenterol 2008;43:736-46.
Welch CS. A note on transplantation of the whole liver in dogs. Transplant Bull 1955;2:54-5.
Wibaux C, Legroux-Gerot I, Dharancy S, et al. Assessing bone status in patients awaiting liver
transplantation. Joint Bone Spine 2011; 78:387-91.
Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil
combination therapy improves long-term outcomes after liver transplantation in
patients with and without hepatitis C. Liver Transpl 2005;11:750-9.
Wigg AJ, Gunson BK, Mutimer DJ. Outcomes following liver transplantation for seronegative
acute liver failure: experience during a 12-year period with more than 100 patients.
Liver Transpl 2005;11:27-34.
Wong PY, Portmann B, O'Grady JG, et al. Recurrence of primary biliary cirrhosis after liver
transplantation following FK506-based immunosuppression. J Hepatol 1993;17:284-7.
Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis B virus recurrence after withdrawal of
long-term hepatitis B immunoglobulin patients receiving maintenance nucleos(t)ide
analogue therapy. Liver Transpl 2007;13:374-81.
Yahyazadeh A, Beckebaum S, Cicinnati V, et al. Efficacy and safety of subcutaneous human
HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int 2011;24:441-50.
Yan ML, Yan LN, Li B, et al. Intramuscular hepatitis B immune globulin combined with
lamivudine in prevention of hepatitis B recurrence after liver transplantation.
Hepatobiliary Pancreat Dis Int 2006;5:360-3.
Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for
hepatocellular carcinoma: validation of the UCSF-expanded criteria based on
preoperative imaging. Am J Transpl 2007;7:2587-96.
Yoshida H, Kato T, Levi DM, et al. Lamivudine monoprophylaxis for liver transplant recipients
with non-replicating hepatitis B virus infection. Clin Transplant 2007;21:166-71.
Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant
recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed,
low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate
mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005;11:1064-72.
Yu L, Ioannou GN. Survival of liver transplant recipients with hemochromatosis in the United
States. Gastroenterology 2007;133:489-95.
Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long term survival after liver
transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005;100:2708-16.
Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation
using lamivudine or lamivudine combined with hepatitis B immunoglobulin
prophylaxis. Liver Transpl 2006;12:253-8.
Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following
liver transplantation for hepatocellular carcinoma. Liver Transpl 2008;14:633-8.
Ziolkowski J, Paczek L, Senatorski G, et al. Renal function after liver transplantation:
calcineurin inhibitor nephrotoxicity. Transplant Proc 2003;35:2307-9.
Zoepf T, Maldonado-Lopez EJ, Hilgard P, et al. Balloon dilatation vs. balloon dilatation plus bile
duct endoprostheses for treatment of anastomotic biliary strictures after liver
transplantation. Liver Transpl 2006;12:88-94.